Summary

Eligibility
for people ages 0-30 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Arun Rangaswami
Headshot of Arun Rangaswami
Arun Rangaswami

Description

Summary

This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).

Official Title

The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates - A Phase II Study

Details

Keywords

Hepatocellular Carcinoma, Childhood, Fibrolamellar Carcinoma, Liver Cancer, Liver Cancer, Pediatric, Hepatocellular Carcinoma Childhood, Liver Cancer Pediatric, Carcinoma, Hepatocellular Carcinoma, Liver Neoplasms, Pembrolizumab

Eligibility

Locations

  • UCSF accepting new patients
    San Francisco California 94143 United States
  • Baylor College of Medicine accepting new patients
    Houston Texas 77030 United States

Lead Scientist at UCSF

  • Arun Rangaswami
    I am one of the senior solid tumor faculty at UCSF, having joined the institution in 2019. My scholarly and clinical practice have focused on the treatment of pediatric liver cancers and rare cancers.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Allison O'Neill, MD
ID
NCT04134559
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 18 study participants
Last Updated